In a regulatory filing yesterday, Grocery Outlet (GO) stated: “Following the issuance of the Company’s Q4 and full year fiscal 2025 outlook on November 4, 2025, the United States government shutdown adversely impacted the disbursement of benefits from federally-funded assistance programs that many of our customers depend on, including the Supplemental Nutrition Assistance Program. As a result, the Company’s preliminary comparable store sales for the calendar month of November 2025 that were made in the form of Electronic Benefits Transfer payments declined by approximately 8.2%. The Company’s preliminary comparable store sales from non-EBT transactions declined by approximately 0.5% for the calendar month of November 2025. Based on these recent sales trends, for the fourth quarter of fiscal 2025, the Company now expects comparable store sales to be approximately flat, and expects its diluted adjusted earnings per share to be at the low end of its previous forecast range of $0.21 to $0.23. For fiscal 2025, the Company now expects comparable store sales growth at the low end of the previously issued guidance range of 0.6% to 0.9% and diluted adjusted earnings per share to be at the low end of the previously issued guidance range of $0.78 to $0.80. The Company is not otherwise providing any update regarding its outlook issued on November 4, 2025.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GO:
- Grocery Outlet Reports Sales Decline Amid Government Shutdown
- Grocery Outlet price target lowered to $13 from $16 at TD Cowen
- Cautious Outlook: Oliver Chen Maintains Hold Rating on Grocery Outlet Holding Corp with Revised Price Target
- Grocery Outlet’s Earnings Call: Growth Amid Challenges
- Trump Trade: Trump in talks with Lilly, Novo on weight loss drug deal
